287 related articles for article (PubMed ID: 25036722)
1. Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).
Szafraniec MJ; Szczygieł M; Urbanska K; Fiedor L
Drug Metab Rev; 2014 Nov; 46(4):459-74. PubMed ID: 25036722
[TBL] [Abstract][Full Text] [Related]
2. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
3. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
4. Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport.
Cai X; Bikadi Z; Ni Z; Lee EW; Wang H; Rosenberg MF; Mao Q
J Pharmacol Exp Ther; 2010 Jun; 333(3):670-81. PubMed ID: 20203106
[TBL] [Abstract][Full Text] [Related]
5. Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity.
Ni Z; Bikadi Z; Shuster DL; Zhao C; Rosenberg MF; Mao Q
Biochemistry; 2011 Sep; 50(37):8057-66. PubMed ID: 21854076
[TBL] [Abstract][Full Text] [Related]
6. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).
Ni Z; Bikadi Z; Rosenberg MF; Mao Q
Curr Drug Metab; 2010 Sep; 11(7):603-17. PubMed ID: 20812902
[TBL] [Abstract][Full Text] [Related]
7. Marine natural products as breast cancer resistance protein inhibitors.
Cherigo L; Lopez D; Martinez-Luis S
Mar Drugs; 2015 Apr; 13(4):2010-29. PubMed ID: 25854646
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
Nakanishi T; Ross DD
Chin J Cancer; 2012 Feb; 31(2):73-99. PubMed ID: 22098950
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
10. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
11. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
Meyer zu Schwabedissen HE; Kroemer HK
Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
Han B; Zhang JT
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
[TBL] [Abstract][Full Text] [Related]
14. Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.
Ni Z; Bikadi Z; Cai X; Rosenberg MF; Mao Q
Am J Physiol Cell Physiol; 2010 Nov; 299(5):C1100-9. PubMed ID: 20739628
[TBL] [Abstract][Full Text] [Related]
15. Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2).
Tan KW; Killeen DP; Li Y; Paxton JW; Birch NP; Scheepens A
Eur J Pharmacol; 2014 Jan; 723():346-52. PubMed ID: 24269959
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors.
Marighetti F; Steggemann K; Hanl M; Wiese M
ChemMedChem; 2013 Jan; 8(1):125-35. PubMed ID: 23150210
[TBL] [Abstract][Full Text] [Related]
17. Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
Tan KW; Cooney J; Jensen D; Li Y; Paxton JW; Birch NP; Scheepens A
Mol Nutr Food Res; 2014 Nov; 58(11):2099-110. PubMed ID: 25044854
[TBL] [Abstract][Full Text] [Related]
18. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
Römermann K; Helmer R; Löscher W
Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
[TBL] [Abstract][Full Text] [Related]
19. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
Imai Y; Tsukahara S; Asada S; Sugimoto Y
Cancer Res; 2004 Jun; 64(12):4346-52. PubMed ID: 15205350
[TBL] [Abstract][Full Text] [Related]
20. Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.
Mao Q; Unadkat JD
AAPS J; 2015 Jan; 17(1):65-82. PubMed ID: 25236865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]